UNSPSC 51112602: Ditiomustine

This classification denotes a nitrosourea compound with the molecular formula C10H18Cl2N6O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 810O95170J, chemically known as 5,6-dithia-2,9,11-triazatridecanamide, 13-chloro-n-(2-chloroethyl)-n,11-dinitroso-10-oxo- but more generally known as ditiomustine, which bears US NIH Compound Identifier 127547. European Medicines Agency schedules Ditiomustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06334MIG.

UNSPSC 51112602 Ditiomustine is a Commodity code representing pharmaceutical products procured by state and local health and human services agencies. State governments use this code to source specific therapeutic medications, including chemotherapy agents and other controlled pharmaceuticals, through formal procurement channels that establish pricing, supply agreements, and distribution relationships with manufacturers and authorized distributors. The Texas Health and Human Services Commission and similar state Medicaid and employee health plan administrators are primary issuing bodies under this code, along with county health departments and public hospital systems that manage pharmacy benefits for state employees, Medicaid beneficiaries, and indigent care populations.

Texas is the primary jurisdiction showing recent activity under this code. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026, with response due April 3, 2026) to gather vendor capability information regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The RFI seeks vendor experience with direct contracting for pharmaceutical supply outside traditional pharmacy benefit manager and group purchasing organization channels, including capacity to negotiate net pricing models, implement outcomes-based agreements, and fulfill volume requirements through dedicated pharmacy partners. This exploratory procurement signals the state's intent to restructure pharmacy benefit procurement and pricing strategy; vendors responding should demonstrate experience with direct-to-employer and direct-to-government-plan contracting within the past two years and flexibility to negotiate outside rebate-based models. The state indicated that this RFI will inform subsequent formal solicitations with established financial parameters and timelines.